The comprehensive and fully integrated platform technology for creating the difference in the Market.
C3 Cura™
Patented augmented absorption technology.
Stabicon Life Sciences’ Innovative C3 Cura™ proprietary product technology platform can
Transform, enhance, bring value to your product portfolio.
It enables a wide set of industry and function specific solutions that allows our customers to elevate productivity and create value.
C3 Cura™ Platform
Highly versatile delivery platform for improving solubility and bioavailability of insoluble and poorly soluble compounds.
Improved potency at lower dose, less toxicity, lower side effects.
Value Proposition
Companies that use this technology platform can gain market exclusivity and patent protection for their products. We are inviting companies across industries to adopt this technology platform to develop novel products and gain competitive advantage. Please feel free to contact us.
Stabicon aims to build long-term partnerships with its customers by sharing C3 Cura™ technology platform solutions to fit your specific challenges and product specifications.
Intellectual Property
Technology Patent Applied For Globally
International Publication Number
WO 2020/084634 A1
Collaborate with us for developing novel product using patented C3 Cura™ Technology so that your product can enjoy premium positioning in the market.
Technology Product Features
It contains extremely fine, taste-masked particles that deliver the drug in the GI tract. The fast dissolving granules that dissolve within seconds in the oral cavity can be taken without water. It also avoids the risk of chocking.
This technology helps to mask the bitter taste of drugs by creating a smooth mouth feel.
Target segments
This technology can be used for paediatric and geriatric product. Moreover, this technology product is best suited for patients who have a restriction in consuming more amount of water and person undergoing dialysis
This provide Convenience on the Go technology can be adapted for different therapeutic segments
Veterinary drugs: Ideal dosage form for veterinary products since animals have difficulty swallowing
The formulation can be customized based on market requirement.
*PCT Application Number is PCT/IB2021/056541
VesiFuzeTM Emulgel* technology
For enhancing permeability
The low permeability of skin limits the number of drugs that can be delivered through the topical route of drug administration. Hydrophilic drugs are poorly absorbed when applied topically, due to low partitioning through the lipid matrix of the stratum corneum. Cutaneous blood flow rapidly clears the absorbed drug, which may result in low tissue levels. The topically applied drugs should reach the site of action to get the therapeutic benefit.
Stabicon has developed VesiFuzeTM Emulgel technology for improving the permeability of drugs through the natural pores in the stratum corneum. It consists of an aqueous gel containing hydrophilic emulgel which is designed to pass through the skin with a permeability enhancer.
Technology Patent Applied For Globally
International Publication Number
WO 2022/175856 A1
Technological Advancements:
Very effective in arthritis and pain management products
Excellent clinical results
Let's Get In Touch!
Ready to start your next project with us? That's great! Give us a call or send us an email and we will get back to you as soon as possible!
